Search Results

You are looking at 41 - 50 of 299 items for :

Clear All
Full access

Sundar Jagannath

Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma (MM) in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the

Full access

Philip L. McCarthy

Multiple myeloma (MM) is an incurable disease. One major goal in the treatment of patients with MM is to improve progression-free and overall survival (PFS and OS, respectively). In the past 10 years, the median OS for patients with MM has

Full access

Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus and Joanne S. Buzaglo

Background Multiple myeloma (MM), a plasma cell malignancy, is the second most common hematologic cancer in the United States, with an estimated 32,110 new cases occurring in 2019, and an estimated 12,960 deaths. 1 Advances in treatment using

Full access

Multiple myeloma will account for an estimated 15,270 (1.1%) new cancer cases in the United States in the year 2004, including 8,090 cases in men (1.2%) and 7,180 (1.1%) cases in women. It will also be responsible for approximately 11,070 (2.0%) cancer deaths in 2004. Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable at present. However, treatment algorithms such as this one (based on published data and clinical experience) can optimize therapy, not only for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre and Natalie S. Callander

Background: Obesity, and in particular severe obesity, is increasingly prevalent in the United States. Epidemiological studies have shown an association in multiple myeloma (MM) between obesity and mortality (Teras et al, Br J Haematol 2014

Full access

Kenneth C. Anderson

Multiple myeloma (MM) is an example of a disease that has seen rapid bench-to-bedside translation of novel agents targeting the tumor in its microenvironment, with clinical trials ultimately leading to FDA approval. Remarkably, 16 new treatments

Full access

8 8 Suppl_1 Suppl_1 Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics Jagannath Sundar MD 02 2010 8 8 Suppl_1 Suppl_1 S-1 S-1 S-3 S-3 0080S-1 10.6004/jnccn.2010.0111 Complications of

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee and Anaadriana Zakarija

include those of the stomach, kidney, uterus, lung, ovary, bladder, and testis. 1 , 21 , 31 In addition, an increased risk of VTE has been observed in certain hematologic malignancies, such as lymphoma, acute leukemia, and multiple myeloma. 1 , 40 , 41

Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang

Background: The role of panobinostat compared to elotuzumab and ixazomib in patients with multiple myeloma(MM) continues to be debated in the context of its complications. Methods: MedLine and Cochrane databases were queried with different MeSH

Full access

Audrey Demaree, Anthony Hewitt, Ben Eckert and Lik Wee Lee

and routine patient management. MRD assessment is now recommended within several lymphoid cancer NCCN guidelines, including multiple myeloma (MM), ALL, and CLL. The clonoSEQ® Assay (Adaptive Biotechnologies; Seattle, WA) is currently the only FDA